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Background/Aims: This study aims to identify the gene mutation pattern associated with antibiotic resistance for mainly used anti-
biotics in Helicobacter pylori strains isolated from Koreans.
Materials and Methods: Seventy-one H. pylori strains were isolated from gastric mucosal biopsy specimens. The specimens were 
cultivated and the resistance to 5 antibiotics were assessed by using agar gel dilution method. DNA sequencing was carried out to 
detect the resistance-related gene mutations.
Results: A point mutation at A2143G of 23S rRNA was observed in all of the clarithromycin resistant strains, but tetracycline re-
sistant strains were not found. Substitution N562Y in penicillin binding protein 1 were observed in an amoxicillin resistant strain 
(minimum inhibitory concentration [MIC] 2.0μg/mL). Eleven (57.8%) out of 19 levofloxacin resistant strains showed amino acid 
substitution at N87K (8 strains), N87I, A88V and D91N in GyrA. The truncation in rdxA was detected in 8 (25.0%) out of 32 metro-
nidazole resistant strains. Two out of the 7 patients who failed in first-line treatment of clarithromycin and amoxicillin showed 
A2143G mutation.
Conclusions: 23S rRNA mutation is closely related to the failure of eradication, however, the fact that five people who have no gene 
mutation failed eradication implies that other factors are related. As MIC levels in clarithromycin and levofloxacin resistance strains 
are getting higher, their appropriate gene mutation is more correlated. (Korean J Helicobacter Up Gastrointest Res 2014;14:95-102)
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INTRODUCTION
Helicobacter pylori eradication from colonized stomach 
leads to healing of gastritis and peptic ulcer disease and 
probably also has beneficial effect on regression of atro-
phic gastritis and prevention of distal gastric cancer.1 
Failure of first-line treatment is usually related to in-
sufficient patient compliance and/or development of anti-
biotic resistance. Most of the patients who still remain H. 
pylori-positive after two consecutive courses of erad-
ication treatment have been infected with an H. pylori 
strain resisting to one or more of the previously used 
antibiotics. To select an appropriate third-line treatment, 
endoscopy followed by bacterial culture and antimicrobial 
susceptibility testing is advisable. Culture-based methods 
offer the opportunity to determine the minimum in-
hibitory concentration (MIC) of antibiotics, they are 
time-consuming and their results show low reprodu-
cibility. Factors such as cell viability, inoculums size, in-
cubation condition, and growth media may affect their 
outcome.2 Molecular-based methods for antibiotic resist-
ance are independent of these factors, and thus they have 
reproducible results and are easily standardized. For these 
useful molecular-based methods, the mechanism of the 
resistance to the major antibiotics and the information of 
resistant patterns in strains isolated from local areas 
should be understood.
Currently clarithromycin (CLA) remains the most pow-
erful antibiotic available against H. pylori with MIC being 
the lowest as compared to the other molecules. Resi-
stance to CLA in H. pylori is caused by point mutations in 
three adjacent 23S rRNA nucleotides, namely at position 
2142, 2143, and 2144.3 The reliable mechanism for tetra-
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cycline (TET) resistance in H. pylori is based upon a nu-
cleotide-base pair substitution in three adjacent 16S rRNA 
residues, namely AGA926-928 → TTC 3 base mutations.4 It 
has been observed that the Ser414 to Arg substitution, 
adjacent to the SKN motif in PBP1, is responsible for 
amoxicillin (AMX) resistance with a significantly increased 
MIC.5
Another study reported that the Asn562 amino acid 
substituted to a Tyr residue in near KTG motif of PBP1.6
In H. pylori, the resistance to levofloxacin (LEV) is 
caused by point mutation in the so-called quinolone re-
sistance determining region (QRDR; located between ami-
no acid position 67 and 106) of the gyrA at amino acids 
position 87, 88, 91, and 97.7 Metronidazole (MET) is ad-
ministered as a prodrug that needs to be activated within 
the target cell through one or two electron reduction 
processes. There are electron acceptors in H. pylori such 
as NAD(P)H flavin nitroreductase (frxA), oxygen-insen-
sitive NAD(P)H nitroreductase (rdxA). And truncation in 
rdxA is more shown than in frxA as MIC level is higher 
in MET resistance.8 Although resistant rate on H. pylori is 
continuously reported, data on gene mutation that influ-
ences on its treatment are not enough. This study aims to 
identify the gene mutation pattern associated with anti-
biotic resistance on mainly used antibiotics in H. pylori 
isolated from Koreans whose gene mutation data were 
not fully analyzed.
MATERIALS AND METHODS
1. Bacterial isolates
Antimicrobial susceptibility was tested against a total of 
71 strains isolated from 71 patients underwent gastric en-
doscopy at the Yongin Severance Hospital of Yonsei 
University, Korea, from July 2009 to December 2010. 
Afterwards, their antibiotic resistance associated with 
gene mutation was identified. Thirty two out of 71 pa-
tients, who had a history of treatments including a 7 day 
first-line treatment with a proton pump inhibitor (PPI, 30 
mg, twice a day), AMX (2,250 mg, three times a day), 
CLA (1,000 mg, twice a day) and a second-line treatment 
with PPI (30 mg, twice a day), bismuth (300 mg, twice a 
day), MET (2,250 mg, twice a day), and TET (1,000 mg, 
four times a day), were included in an eradication 
treatment. The eradication of H. pylori is verified in case 
of being negative in 13C-urea breath test (Isotechnika, 
Edmonton, AB, Canada) after two months of drug 
administration.
This study was approved by the institutional review 
board of Yonsei University College of Medicine (No. 
4-2011-0508).
2. Culture conditions
The medium used in this study was composed of 
Brucella broth (BBL, Sparks, MD, USA) containing 1.2% 
agar, 10% bovine serum and selected antibiotics (Oxoid 
Limited, Hampshire, UK) (10μg/mL of vancomycin, 5μg/ 
mL of trimethoprim, 5μg/mL of cefsulodin, and 5μg/mL 
of amphotericin B). The fully minced biopsy specimens 
were incubated under 10% CO2, 5% O2 and 100% humid-
ity at 37oC for 3∼5 days. The H. pylori American Type 
Culture Collection (ATCC) 43504 and H. pylori strain 51 
were cultured using the same methods described above 
for standard and quality control assessment.
3. Determination of MICs
Determination of MICs were examined for CLA (Sigma- 
Aldrich Co., St. Louis, MO, USA), TET (Sigma-Aldrich Co.), 
AMX (Sigma-Aldrich Co.), LEV (Sigma-Aldrich Co.), and 
MET (Sigma-Aldrich Co.) by slightly modified (Brucella 
broth base with 1.2% agar) agar dilution method recom-
mended by the Clinical and Laboratory Standards Institute. 
CLA resistance was defined according to the Clinical and 
Laboratory Standards Institute approved breakpoint (≥1 
μg/mL).9 Isolates were classified as resistant to TET, 
AMX, LEV, and MET when the MICs were ≥4, ≥1, ≥1 
and ≥8μg/mL respectively. H. pylori ATCC 43504 was 
used for quality control of the selective medium and anti-
microbial susceptibility test. For H. pylori ATCC 43504, 
the MIC range of CLA was 0.016∼0.125μg/mL, TET 
0.125∼1μg/mL, AMX 0.016∼0.125μg/mL, LEV 0.064∼
0.5μg/mL, and MET 64∼256μg/mL.
4. PCR and sequencing analysis
DNA extraction was performed on colonies that were 
isolated from the gastric biopsy using AccuPrep Genomic 
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Table 1. Oligonucleotides Used in This Study
Target gene  Primer  Oligonucleotides sequence (5’-3’)a Positionb
Annealing 
temperature
Reference 
Helicobacter pylori  
16S rRNA 
 HPU185 CCTACGGGGGAAAGATTTAT 185 to 204, forward 52oC 10
 HPU826  AGCTGCATTACTGGAGAGACT 806 to 826, reverse
rrn 23S  rrn23S-F ATGAATGGCGTAACGAGATG  2051 to 2070, forward 52oC  This study
 This study
 This study
 This study
 This study
 This study
  (23S rRNA gene)  rrn23S-R GTCTTACAGTCAGGCTGGCT 2420 to 2439, reverse
　  rrn24S-SF GAGATGGGAGCTGTCTCA 　 　
rrn 16S  rrn16S-F TGCAGCTAACGCATTAAGCATC 818 to 839, forward 54oC 
  (16S rRNA gene)  rrn16S-R GAGGCAGTATCCTTAGAGTTCT  1110 to 1131, reverse
　  rrn16S-SF AAGCATCCCGCCTGGGG 　 　
pbp1  pbp1-F CCACGCAAGCCAAACGGC 1076 to 1093, forward 58oC 
 pbp1-R CCTTTGGGGACATCAAACTTT 1857 to 1877, reverse
 pbp1-SF ATCGCTTTTGATAATGGCTATT 　 　
gyrA  gyrA-F GTGCATAGGCGTATTTTGTATG 142 to 163, forward 52oC 
 gyrA-R CATTCTGGCTTCAGTGTAACG  373 to 393, reverse
 gyrA-SF GCGTATTTTGTATGCGATGC 　 　
rdxA  rdxA-F1 TAGGGATTTTATTGTATGCTACG 969932 to 969911, forward 52oC 
 rdxA-R1 CCACAGCGATATAGCATTGCT 969458 to 969435, reverse
 rdxA-SF1 GTATGCTACGAAAAATTCTAAA 
 rdxA-F2 GTTAGAGTGATCCCGTCTTTT 969543 to 969516, forward 52oC 
 rdxA-R2 CCTAAAAGAGCGATTAAAACCA 969181 to 969161, reverse
 rdxA-SF2 TGCTTGGCGTGAGATTCAA 　 　
aOligonucleotides used for amplification were based on the published genome sequence of Helicobacter pylori strain 51 (GenBank accession 
CP000012). bPosition of oligonucleotides are given to the mutation of antibiotics resistance of H. pylori.
Table 2. Distribution of Minimum Inhibitory Concentrations (MICs) for the 71 Helicobacter pylori Isolates Tested
MICs (μg/mL)  
Number of strains (%)
Clarithromycin  Tetracycline  Amoxicillin   Levofloxacin  Metronidazole  
0.016 4 (5.6)  14 (19.7)  　
0.032 43 (60.6)  11 (15.5) 　
0.064 18 (25.4) 12 (16.9) 17 (23.9)  　
0.125  13 (18.3) 18 (25.4) 2 (2.8) 　
0.25 35 (49.3) 7 (9.9) 20 (28.2) 1 (1.4) 
0.5 1 (1.4) 8 (11.3) 2 (2.8) 30 (42.3) 2 (2.8) 
1  2 (2.8) 1 (1.4) 4 (5.6) 2 (2.8) 
2  1 (1.4) 1 (1.4) 3 (4.2) 24 (33.8) 
4 1 (1.4)   2 (2.8) 10 (14.1) 
8 1 (1.4)   5 (7.0) 11 (15.5) 
16 2 (2.8)  2 (2.8) 5 (7.0) 
32   3 (4.2) 5 (7.0) 
64    7 (9.9) 
128 1 (1.4)   3 (4.2) 
256    1 (1.4) 
Numbers indicated in bold represent resistant strains to respective antibiotics.
DNA Extraction Kit (Bioneer Co., Daejeon, Korea). The 
PCR primer was designed using the Oligo Program Ver-
sion 6 (Molecular Biology Insights Inc., Cascade, CO, USA) 
shown in Table 1.10 The template DNA (2μL) was added 
to 18μL aliquots of AccuPower PCR PreMix (Bioneer 
Co.). PCR was performed with initial denaturation at 94oC 
for 5 min, followed by 35 cycles with denaturation at 
94oC for 50 sec, annealing at appropriate temperature 
(Table 1) for 50 sec and elongation step at 72oC for 1 
min. Cycling was followed by a final extension at 72oC 
for 7 min. The amplification reactions were performed 
with a thermal cycler (GenePro Thermal Cycler BIOER, 
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Fig. 1. The correlation of minimum 
inhibitory concentration against cla-
rithromycin with Helicobacter pylori
23S rRNA gene mutations (A) and 
against tetracycline with Helicobac-
ter pylori 16S rRNA gene mutations 
(B). Genetic sequencer were based on 
the published genome sequence of 
Helicobacter pylori strain 51 (Gen-
Bank accession CP000012). MIC, 
minimum inhibitory concentration.
Tokyo, Japan). Amplification products were separated by 
a 1.5% agarose gel electrophoresis, stained with 0.5μg/mL 
ethidium bromide and visualized using a ultraviolet 
trans-illuminator (Vilber Louramat, Mame La Valle, France). 
DNA sequencing was carried out at Macrogen (Seoul, 
Korea). The resulting consensus sequences were com-
pared to GenBank (www.ncbi.nlm.nih.gov/GenBank) ref-
erence sequence of H. pylori strain 51.
RESULTS
The MICs distributions for the 71 clinical isolates are 
described in Table 2. The clinical resistance rate shows 
CLA at 7.0%, TET at 0%, AMX at 2.8%, LEV at 26.8%, and 
MET at 45.1%. For the area of 163 bp (position 2137∼
2299) of 23S rRNA gene, six susceptible strains and five 
resistance strains are analyzed to identify their base se-
quences as shown in Fig. 1A. A2143G point mutation was 
observed in all the five resistant strains including strain 
No. 76, No. 37, No. 6, No. 91, and No. 44. But the muta-
tion of T2182 and A2223 was observed in both resistant 
and susceptible groups. The TET-resistant H. pylori strain 
(MIC value of ≥4μg/mL) was not observed in this study. 
No substitution was occurred in the region of AGA926-928 
in 16S rRNA gene. The C989T, T1103C, G1121A, and 
A1122T mutations did not appear to be consistent with 
the MIC results as shown in Fig. 1B.
For the area of 228 amino acids of pbp1 gene, eight 
susceptible stains and two resistant strains are analyzed to 
identify their base sequences as shown in Fig. 2A. No 
substitution occurred in the position S414; a region 
known as AMX-resistant. Substitutions of I515M, K518R, 
T558S, N562Y, and G594S occurred in resistant strain No. 
44 (MIC 2μg/mL). In the strains No. 91 (MIC 0.5μg/mL) 
and No. 17 (MIC 1μg/mL), N was inserted at position 
463 and substitutions of G591R, T593S and G594S occurred.
QRDR amino acid regions in gyrA were identified in 19 
strains of LEV-resistant H. pylori as shown in Fig. 2B. 
N87K substitution was found in 8 strains and N87I, A88V 
and D91N substitutions in 3 strains, respectively. The full 
length amino acids in rdxA were identified in 32 strains 
of MET-resistant H. pylori as shown in Table 3. Genetic 
truncation appeared in five out of 8 strains, whose muta-
tions were consequently substituted with stop codons. 
The other three strains, two of which were deleted and 
one of which was inserted, were finally frameshifted.
Thirty-two patients were monitored for the eradication 
program as shown in Table 4. The eradication with the 
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Fig. 2. The correlation of minimum 
inhibitory concentration against amo-
xicillin with PBP1 mutations (A) and 
against levofloxacin with GyrA mu-
tations (B). Genetic sequencer were 
based on the published genome se-
quence of Helicobacter pylori strain 
51 (GenBank accession CP000012). 
*Amino acid insertion and **dele-
tion. MIC, minimum inhibitory con-
centration.
Table 3. Genetic Truncation in rdxA of Helicobacter pylori 
Strain No.  (MIC, μg/mL)  Substitution 
31 (8)  CAG150-152 →  TAG  Q 50 Stop 
36 (16)  TTA AT459-463 →  **A AT  L 153 Frameshift 
71 (32)  GAA399-401 →  TAA  E 133 Stop
17 (64)  CAA195-197 → TAA  Q 65 Stop
64 (64)  AAC378-380 →  AA(AA)C  N 126 Frameshift 
100 (64)  CAG150-152 → TAG  Q 50 Stop
75 (128)  CAG150-152 →  TAG  Q 50 Stop
47 (256)  TAC ATG GCA AAA300-311 → TA* *** *** AAA  Y 100 Frameshift 
MIC, minimum inhibitory concentration.
*Deletion and ( ) insertion of 2 nucleotides.
first-line therapy was achieved in 82.7% (24/29) in the 
strains susceptible to both CLA and AMX. The CLA-sus-
ceptible and AMX-resistant isolate was successful in erad-
ication, also. However the first-line therapy was failed in 
five isolates, even though those were susceptible both to 
CLA and AMX and had no gene mutations. The erad-
ication in 2 CLA-resistant and AMS-susceptible isolates 
were failed with the first-line therapy, but were success-
ful with the second-line therapy. The mutations found in 
these strains were A2143G mutation in 23S rRNA.
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Table 4. The Effect of Eradication and Gene Mutation of Helicobacter pylori Isolated from Treatment Group
1st 2nd 
 Strain No.   Gene mutation 
Clarithromycin  Amoxicillin  
Eradication 
(Number of patients) 
Metronidazole   Tetracycline  Eradication 
S S Succeeded (24) No
Failed (5) S S Succeeded 20 No 
S S Failed 63 
S S No record 74 
S S No record 40 
R S No record 93 
R S Failed (2) S S Succeeded 6, 37 23S rRNA A2143G
S R Succeeded (1) 17 No
Gene mutations regions were targeted at 23S rRNA gene in clarithromycin, at pbp1 in amoxicillin, at rdxA in metronidazole and at 16S rRNA gene 
in tetracycline. S, susceptible; R, resistant.
DISCUSSION
The eradication rate of H. pylori infection is generally 
around 70∼95%, and the antibiotic resistance is consid-
ered to be the main factor of eradication failure. Antimi-
crobial susceptibility test in H. pylori is generally per-
formed in a culture-based method, which takes about 6 
to 10 days. Moreover, comparing the results with other 
organizations is not easy due to the lack of standardi-
zation. On the contrary, molecular-based methods are in-
dependent of cell viability and growth rates of the bac-
teria and are easily standardized. 
In this study, the molecular patterns in relation to H. 
pylori resistance to 5 antibiotics were investigated based 
on the antimicrobial susceptibility test and the eradication 
rate.
The resistant strains to CLA were 7.0% (5/71), and MIC 
range was 4∼128μg/mL. The MIC range of the CLA-sus-
ceptible strains was low (0.016∼0.5μg/mL), with a strik-
ing difference in the peaks of the two groups. This in-
dicated that a certain factor is responsible for determining 
the resistance to CLA. In macrolides, point mutations in 
23S rRNA are known to decrease the affinity of anti-
biotics to ribosomes. Only A2143G mutation occurs in all 
the five strains, whose base sequences can be identified 
in CLA-resistant group, and it corresponds to their MIC 
value. 
In this study, A2142G/C and A2144G mutations known 
to be responsible for resistance did not occur. In the 
United States, A2143/2144G was reported in 97% of H. 
pylori strains, A2143C in 7%.11 In Japan, A2143/2144G 
was reported in 100%.12 However, T2182 and A2223 are 
considered as non-specific genetic polymorphism since 
they occur in both resistant and susceptible groups. 
TET resistance of H. pylori is based on triple-bp sub-
stitution in three adjacent 16S rRNA residues, namely 
AGA926-928→TTC. In this study, TET resistance was not 
observed in strains that show MICs of ≥4μg/mL and the 
strains within MICs of 0.06, 0.25, 0.5, 1, and 2μg/mL did 
not show any AGA926-928 mutations. However, the C989T, 
T1103C, G1121A and A1122T mutations are considered to 
be inconsistent with the MIC results. According to other 
studies, triple-bp substitutions (i.e., A926G, A926T, 
A928C, AG926-927 GT, and A926G/A928C) have been re-
ported to be involved in TET resistance in H. pylori.4 
Therefore, the use of the molecular method is considered 
useful to detect AGA926-928 mutation in a high level of 
MIC.
The AMX-resistant strains were 2.8% (2/71) with a MIC 
range of 1∼2μg/mL and susceptible group showed the 
lowest MIC among the tested 5 antibiotics. Although re-
sistance was observed at the cut-off value of ≥1μg/mL, 
and it was observed only in the strain No. 44 (MIC 2μg/mL) 
in relation to the resistant mutation of pbp1 gene, and 
substitution with N562Y was considered as a major cause. 
In S414R known as the cause of AMX resistance, sub-
stitution did not occur. Substitutions of various amino 
acids near the motif are considered to influence the MIC 
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values, so more investigations are required from diverse 
types of mutations concerning with resistance.
Resistance to fluoroquinolones sharply increased within 
a short period. A local study reported that the LEV resist-
ance had increased from 4.5% in 2003∼2005 to 29.5% in 
2005∼2007.13 Likewise, this study showed the similar re-
sults within 26.8% of resistance. The mutations in the 
QRDR regions of the gyrA were observed in 57.8% 
(11/19) of the LEV-resistant strains. N87K is the most 
common substitution followed by N87I, A88V, and D91N. 
The higher the MIC values were, the more distinctive the 
mutations were, which shows more correlation.
The MET-resistant strains were 45.1% (32/71) with a 
MIC range of 0.25∼256μg/mL which is the highest 
among the 5 antibiotics. The MET-resistant strains were 
20∼40% in the United States and Europe and 50∼80% in 
developing countries. Recent studies in Korea reported 
that MET-resistant strains were 10∼27%.14 Despite this 
resistance rate, the use of MET has steadily increased be-
cause of its eradication efficacy, which is as effective as 
CLA. In this study, a full-length amino acid was analyzed 
in the rdxA of MET-resistant strains and rdxA truncation 
was observed in 25.0% (8/32). Five strains came to have a 
stop codon due to point mutation. A frameshift occurred 
in 3 strains due to deletion and insertion. These genetic 
truncations showed a trend that occurs more at a high 
MIC than at a low MIC. Studies have shown that the di-
versity of the MIC levels was caused by the involvement 
of several electron acceptors and that the resistance to 
MET disappeared under low oxygen conditions.15 There-
fore, it is meaningful to identify rdxA mutation by the 
molecular detection method for MET resistance and it is 
also required to identify other several genes that are in-
volved in the reductase. 
As MIC levels in CLA, AMX, and LEV resistance strains 
are getting higher, their gene mutation is more correlated. 
Afterwards, the TET resistance stains are required more 
case studies to find more information about its gene 
mutation. In our study, the reason why resistant rate is 
somewhat low in the same period is that many of the pa-
tients have no eradication therapy history of H. pylori 
infection. Also, regional factors are considered to have an 
influence on it. Though two strains, No. 37 (MIC 8μg/mL) 
and No. 6 (MIC 16μg/mL), from the 7 patients who 
failed in first-line treatment of CLA and AMX are 
AMX-susceptible, A2143G mutation of CLA-resistant is 
considered to effect on eradication failure. However, the 
other 5 strains failed in eradication, even though they are 
susceptible and have no gene mutation. We could not 
find the reason for eradication failure in our study and 
insufficient patient compliance or heteroresistance strains 
might be the possible factors, according to the previous 
paper.16 On the other hand, eradication was possible in 
the strain No. 17 (MIC 1μg/mL), which was CLA-suscep-
tible. In combined treatment, AMX-resistance is less influ-
ential than CLA-resistant strains. For these useful molec-
ular-based methods, the mechanism of the resistance to 
the major antibiotics and the information of resistant pat-
terns in strains isolated from local areas should be 
understood.
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